Company / PP&E per Share
Dianthus Therapeutics, Inc. /DE/ PP&E per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$0.01
FY2025
5-year range
$0.01 / $0.16
FY2021-FY2025
Trend
-27.3%
vs FY2024
Sector context
#162 of 191
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s pp&e per share of $0.01 is lower than 85% of companies in the Health Care sector (FY2025). PP&E per Share has declined for 3 consecutive years, from $0.16 in FY2022 to $0.01 in FY2025.
Based on SEC 10-K filings.
0.01 in FY2025 with a 5-year CAGR of -45.0%.
Declined from $0.04 to $0.01 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -61.2%
- 5-Year CAGR
- -45.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 191This company $0.01 Sector average $18.90
▼
-99.9% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s pp&e per share has declined for 3 consecutive years.
- In FY2025, pp&e per share decreased 27.3% year-over-year.
- Ranks #162 out of 191 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | -27.3% |
| FY2024 | $0.01 | -63.5% |
| FY2023 | $0.04 | -77.9% |
| FY2022 | $0.16 | +19.6% |
| FY2021 | $0.14 | -28.3% |
| FY2020 | $0.19 | -36.3% |
| FY2019 | $0.30 | -93.2% |
| FY2018 | $4.34 | +312.3% |
| FY2017 | $1.05 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026